Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma
JCO Precision Oncology · 2024-10 · (8)
DOI: 10.1200/po.24.00334 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-10. Verfasst von Gianna Kroening und 16 weiteren Autor:innen. Beteiligte Einrichtung: University of California Irvine School of Medicine, Orange, CA. Hauptthemen laut MEDLINE: Nuclear Proteins. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Nuclear protein in testis carcinoma (NC) is an underdiagnosed and aggressive squamous/poorly differentiated cancer characterized by rearrangement of the gene NUTM1 on chromosome 15q14. Co-occurring alternations have not been fully characterized. METHODS We analyzed the genomic and immune landscape of 54 cases of NC that underwent DNA- and RNA-based NGS sequencing (Caris). RESULTS While NC is driven by NUTM1 fusion oncoproteins, co-occurring DNA mutations in epigenetic or cell cycle pathways were observed in 26% of cases. There was no significant difference between the fusion partner of NUTM1 and co-occurring gene mutations. RNA sequencing analysis showed increased MYC pathway activity in NC compared with head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma (LUSC), which is consistent with the known pathophysiology of NC. Characterization of the NC tumor microenvironment using RNA sequencing revealed significantly lower immune cell infiltration compared with HNSCC and LUSC. NC was 10× higher in patients with HNSCC and LUSC younger than 50 years than in those older than 70 years. CONCLUSION To our knowledge, this is the first series of NC profiled broadly at the DNA and RNA level. We observed fewer intratumoral immune cells by RNA sequencing, which may be associated with anecdotal data of lack of immunotherapy benefit in NC. High MYC pathway activity in NC supports ongoing trials targeting MYC suppression. The incidence of NC among patients younger than 50 years with LUSC/HNSCC supports testing for NC in these patients. The prognosis of NCs remains dismal, and future studies should focus on improving the response to immunotherapy and targeting MYC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of California Irvine School of Medicine, Orange, CA.
- Dana-Farber Cancer Institute, Boston, MA.
- Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
- Caris Life Sciences, Phoenix, AZ.
- University of Cincinnati, Cincinnati, OH.
- Karmanos Cancer Institute, Detroit, MI.
ORCID-Profile: Gianna Kroening, Jia Luo, Mark G Evans, Sai-Hong Ignatius Ou, Zhaohui L Arter, Trisha M Wise-Draper, Asfar S Azmi, David R Braxton, Matthew J Oberley, Chul Kim, Geoffrey I Shapiro, Christopher A French, Misako Nagasaka
Zitieren
APA
Kroening, G., Luo, J., Evans, M. G., Adeyelu, T., Ou, S. I., Arter, Z. L., Wise-Draper, T. M., Sukari, A., Azmi, A. S., Braxton, D. R., Elliott, A., Bryant, D. A., Oberley, M. J., Kim, C., Shapiro, G. I., French, C. A., & Nagasaka, M. (2024). Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma. JCO Precision Oncology. https://doi.org/10.1200/po.24.00334
Vancouver
Kroening G, Luo J, Evans MG, Adeyelu T, Ou SI, Arter ZL, et al. Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma. JCO Precision Oncology. 2024. doi:10.1200/po.24.00334
BibTeX
@article{Kroening2024,
author = {Kroening, Gianna and Luo, Jia and Evans, Mark G and Adeyelu, Tolulope and Ou, Sai-Hong Ignatius and Arter, Zhaohui L and Wise-Draper, Trisha M and Sukari, Ammar and Azmi, Asfar S and Braxton, David R and Elliott, Andrew and Bryant, David A and Oberley, Matthew J and Kim, Chul and Shapiro, Geoffrey I and French, Christopher A and Nagasaka, Misako},
title = {Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma},
journal = {JCO Precision Oncology},
year = {2024},
number = {8},
doi = {10.1200/po.24.00334}
}
EUVIMED